{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:45:24Z","timestamp":1792273524579,"version":"4.4.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00198-026-07999-3","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T14:32:11Z","timestamp":1776177131000},"page":"1843-1854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Romosozumab super-responders in clinical practice: insights from a large Italian multicenter cohort of women with severe postmenopausal osteoporosis"],"prefix":"10.1007","volume":"37","author":[{"given":"Alberto","family":"Ghielmetti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgia","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Carrara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Palermo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anda","family":"Naciu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Sargentini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Salcuni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Vescini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Zampogna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Atlasova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Rondinella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberta","family":"Cosso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iacopo","family":"Chiodini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittoria","family":"Favero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimiliano","family":"Mazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Frara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanna","family":"Mantovani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Corbetta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6805-5804","authenticated-orcid":false,"given":"Cristina","family":"Eller-Vainicher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"1","key":"7999_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-021-00969-8","volume":"17","author":"C Willers","year":"2022","unstructured":"Willers C, Norton N, Harvey NC, Jacobson T, Johansson H, Lorentzon M, McCloskey EV, Borgstr\u00f6m F, Kanis JA, SCOPE review panel of the IOF (2022) Osteoporosis in Europe: a compendium of country-specific reports. Arch Osteoporos 17(1):23. https:\/\/doi.org\/10.1007\/s11657-021-00969-8","journal-title":"Arch Osteoporos"},{"issue":"16","key":"7999_CR2","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMOA1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, Crittenden DB, Adachi JD et al (2016) Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med 375(16):1532\u20131543. https:\/\/doi.org\/10.1056\/NEJMOA1607948","journal-title":"N Engl J Med"},{"issue":"15","key":"7999_CR3","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMOA1708322McClung","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis. N Engl J Med 377(15):1417\u20131427. https:\/\/doi.org\/10.1056\/NEJMOA1708322McClung","journal-title":"N Engl J Med"},{"issue":"3","key":"7999_CR4","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/S00774-019-01057-1","volume":"38","author":"J Takada","year":"2020","unstructured":"Takada J, Dinavahi R, Miyauchi A et al (2020) Relationship between P1NP, a biochemical marker of bone turnover, and bone mineral density in patients transitioned from alendronate to romosozumab or teriparatide: a post hoc analysis of the STRUCTURE trial. J Bone Miner Metab 38(3):310\u2013315. https:\/\/doi.org\/10.1007\/S00774-019-01057-1","journal-title":"J Bone Miner Metab"},{"issue":"10","key":"7999_CR5","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/S00198-021-05925-3","volume":"32","author":"A Tominaga","year":"2021","unstructured":"Tominaga A, Wada K, Okazaki K et al (2021) Early clinical effects, safety, and predictors of the effects of romosozumab treatment in osteoporosis patients: one-year study. Osteoporos Int 32(10):1999\u20132009. https:\/\/doi.org\/10.1007\/S00198-021-05925-3","journal-title":"Osteoporos Int"},{"issue":"6","key":"7999_CR6","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1007\/S00198-021-06261-2","volume":"33","author":"A Tominaga","year":"2022","unstructured":"Tominaga A, Wada K, Okazaki K et al (2022) Effect of the duration of previous osteoporosis treatment on the effect of romosozumab treatment. Osteoporos Int 33(6):1265\u20131273. https:\/\/doi.org\/10.1007\/S00198-021-06261-2","journal-title":"Osteoporos Int"},{"issue":"2","key":"7999_CR7","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/S00223-023-01087-Y","volume":"113","author":"A Tominaga","year":"2023","unstructured":"Tominaga A, Wada K, Okazaki K et al (2023) Nonresponder considerations for romosozumab treatment. Calcif Tissue Int 113(2):157\u2013165. https:\/\/doi.org\/10.1007\/S00223-023-01087-Y","journal-title":"Calcif Tissue Int"},{"issue":"9","key":"7999_CR8","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/S00198-024-07155-9","volume":"35","author":"J Everts-Graber","year":"2024","unstructured":"Everts-Graber J, Wenger M, Oser S et al (2024) The effect of romosozumab on bone mineral density depending on prior treatment: a prospective, multicentre cohort study in Switzerland. Osteoporos Int 35(9):1605\u20131613. https:\/\/doi.org\/10.1007\/S00198-024-07155-9","journal-title":"Osteoporos Int"},{"key":"7999_CR9","doi-asserted-by":"publisher","unstructured":"Adami G, Bartezaghi M, Filippo Montanari, Anna Piccinelli, Francesco Pollastri, Francesca Mastropaolo, Francesco Giorgio, Camilla Benini, Angelo Fassio, Maurizio Rossini, Davide Gatti, Rachele Fornari, Ombretta Viapiana Romosozumab early experience in female patients with severe osteoporosis in an Italian real-world setting, the ROMEO study. Osteoporos Int 2025 Oct 13. https:\/\/doi.org\/10.1007\/s00198-025-07722-8","DOI":"10.1007\/s00198-025-07722-8"},{"key":"7999_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2021.105219","author":"K Ebina","year":"2021","unstructured":"Ebina K, Tsuboi H, Nagayama Y et al (2021) Effects of prior osteoporosis treatment on 12-month treatment response of romosozumab in patients with postmenopausal osteoporosis. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2021.105219","journal-title":"Joint Bone Spine"},{"issue":"12","key":"7999_CR11","doi-asserted-by":"publisher","first-page":"2437","DOI":"10.1007\/S00198-019-05146-9","volume":"30","author":"DL Kendler","year":"2019","unstructured":"Kendler DL, Bone HG, Massari F et al (2019) Bone mineral density gains with a second 12-month course of romosozumab therapy following placebo or denosumab. Osteoporos Int 30(12):2437\u20132448. https:\/\/doi.org\/10.1007\/S00198-019-05146-9","journal-title":"Osteoporos Int"},{"issue":"6","key":"7999_CR12","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1007\/S00198-021-06174-0","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, Kendler DL, Langdahl BL et al (2022) Romosozumab and antiresorptive treatment: the importance of treatment sequence. Osteoporos Int 33(6):1243\u20131256. https:\/\/doi.org\/10.1007\/S00198-021-06174-0","journal-title":"Osteoporos Int"},{"key":"7999_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/JBM4.10512","author":"MR McClung","year":"2021","unstructured":"McClung MR, Bolognese MA, Brown JP et al (2021) Skeletal responses to romosozumab after 12 months of denosumab. JBMR plus. https:\/\/doi.org\/10.1002\/JBM4.10512","journal-title":"JBMR plus"},{"key":"7999_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2024.105754","author":"M Krikelis","year":"2024","unstructured":"Krikelis M, Gazi S, Trovas G et al (2024) Progression of multiple vertebral fractures after denosumab discontinuation under treatment with romosozumab. A case-report. Joint Bone Spine. https:\/\/doi.org\/10.1016\/j.jbspin.2024.105754","journal-title":"Joint Bone Spine"},{"key":"7999_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115574","volume":"140","author":"K Ebina","year":"2020","unstructured":"Ebina K, Hirao M, Tsuboi H, Nagayama Y, Kashii M, Kaneshiro S, Miyama A, Nakaya H, Kunugiza Y, Okamura G, Etani Y, Takami K, Goshima A (2020) NakataK Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140:115574. https:\/\/doi.org\/10.1016\/j.bone.2020.115574","journal-title":"Bone"},{"key":"7999_CR16","doi-asserted-by":"publisher","unstructured":"Ebina K, Kobayakawa T, Etani Y, Noguchi T, Kashii M, Okamura G, Nagayama Y, Tsuboi H, Miyama A, Hirao M, Fukuda Y, Kurihara T, Sugimoto A, Ken Nakata 9, Okada S. Impact of prior teriparatide treatment on the effectiveness of romosozumab in patients with postmenopausal osteoporosis: A case-control study. Bone 2025 https:\/\/doi.org\/10.1016\/j.bone.2025.117389.","DOI":"10.1016\/j.bone.2025.117389"},{"key":"7999_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.bonr.2020.100288","author":"M Kashii","year":"2020","unstructured":"Kashii M, Ebina K, Kitaguchi K, Yoshikawa H (2020) Romosozumab was not effective in preventing multiple spontaneous clinical vertebral fractures after denosumab discontinuation: a case report. Bone Rep. https:\/\/doi.org\/10.1016\/j.bonr.2020.100288","journal-title":"Bone Rep"},{"issue":"3","key":"7999_CR18","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1007\/s00198-022-06642-1","volume":"34","author":"M Kashii","year":"2023","unstructured":"Kashii M, Kamatani T, Nagayama Y, Miyama A, Tsuboi H, Ebina K (2023) Baseline serum PINP level is associated with the increase in hip bone mineral density seen with romosozumab treatment in previously untreated women with osteoporosis. Osteoporos Int 34(3):563\u2013572. https:\/\/doi.org\/10.1007\/s00198-022-06642-1","journal-title":"Osteoporos Int"},{"key":"7999_CR19","unstructured":"Agenzia Italiana del Farmaco (AIFA). Nota 79. 11 February 2025; Available from: https:\/\/www.aifa.gov.it\/en\/nota-79"},{"issue":"9","key":"7999_CR20","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1002\/jbmr.5650080915","volume":"8","author":"HK Genant","year":"1993","unstructured":"Genant HK, Wu CY, van Kuijk C, Nevitt MC (1993) Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8(9):1137\u20131148","journal-title":"J Bone Miner Res"},{"issue":"4","key":"7999_CR21","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1002\/jbmr.1496","volume":"27","author":"A D\u00edez-P\u00e9rez","year":"2012","unstructured":"D\u00edez-P\u00e9rez A, Olmos JM, Nogu\u00e9s X, Sosa M, D\u00edaz-Curiel M, P\u00e9rezCastrill\u00f3n JL, P\u00e9rez-Cano R, Mu\u00f1oz-Torres M, Torrijos A, Jodar E, Del Rio L, Caeiro-Rey JR, Farrerons J, Vila J, Arnaud C, Gonz\u00e1lezMac\u00edas J (2012) Risk factors for prediction of inadequate response to antiresorptives. J Bone Miner Res 27(4):817\u2013824","journal-title":"J Bone Miner Res"},{"key":"7999_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/JCM14092958","author":"JY Park","year":"2025","unstructured":"Park JY, Park HM, Song JY et al (2025) Real-world evaluation of 12-month romosozumab treatment in Korean women with severe osteoporosis: potential synergy with hormone therapy. J Clin Med. https:\/\/doi.org\/10.3390\/JCM14092958","journal-title":"J Clin Med"},{"issue":"3","key":"7999_CR23","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jocd.2018.11.004","volume":"23","author":"L Humbert","year":"2020","unstructured":"Humbert L, Bagu\u00e9 A, Di Gregorio S, Winzenrieth R, Sevillano X, Gonz\u00e1lez Ballester MA, Del Rio L (2020) DXA-based 3D analysis of the cortical and trabecular bone of hip fracture postmenopausal women: a case-control study. J Clin Densitom 23(3):403\u2013410. https:\/\/doi.org\/10.1016\/j.jocd.2018.11.004","journal-title":"J Clin Densitom"},{"issue":"4","key":"7999_CR24","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1093\/jbmr\/zjae028","volume":"39","author":"EM Lewiecki","year":"2024","unstructured":"Lewiecki EM, Betah D, Humbert L, Libanati C, Oates M, Shi Y, Winzenrieth R, Ferrari S, Omura F (2024) 3d-modeling from hip DXA shows improved bone structure with romosozumab followed by denosumab or alendronate. J Bone Miner Res 39(4):473\u2013483. https:\/\/doi.org\/10.1093\/jbmr\/zjae028","journal-title":"J Bone Miner Res"},{"issue":"11","key":"7999_CR25","doi-asserted-by":"publisher","DOI":"10.1093\/jbmrpl\/ziaf151","volume":"9","author":"EM Lewiecki","year":"2025","unstructured":"Lewiecki EM, Betah D, Humbert L, Libanati C, Oates M, Shi Y, Winzenrieth R, Ferrari S, Omura F (2025) Effects of romosozumab and teriparatide on hip bone using 3D-SHAPER in postmenopausal women with osteoporosis. JBMR Plus 9(11):ziaf151. https:\/\/doi.org\/10.1093\/jbmrpl\/ziaf151","journal-title":"JBMR Plus"},{"issue":"5","key":"7999_CR26","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/joim.12587","volume":"281","author":"D Sundh","year":"2017","unstructured":"Sundh D, Nilsson AG, Nilsson M, Johansson L, Mellstr\u00f6m D, Lorentzon M (2017) Increased cortical porosity in women with hip fracture. J Intern Med 281(5):496\u2013506. https:\/\/doi.org\/10.1111\/joim.12587","journal-title":"J Intern Med"},{"key":"7999_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2025.117701","volume":"202","author":"E Gielen","year":"2026","unstructured":"Gielen E, Amini N, Coppens D, Dejaeger M, Dupont J, De Vlam K, Rossini M, Viapiana O, Laurent MR, Adami G (2026) Bone mineral density response to romosozumab in post-menopausal women: a prospective observational real-world study. Bone 202:117701. https:\/\/doi.org\/10.1016\/j.bone.2025.117701","journal-title":"Bone"},{"issue":"5","key":"7999_CR28","doi-asserted-by":"publisher","first-page":"e1640","DOI":"10.1210\/clinem\/dgae484","volume":"110","author":"M Hartz","year":"2025","unstructured":"Hartz M, Johannessen FB, Harsl\u00f8f T, Langdahl BL (2025) The effectiveness and safety of romosozumab and teriparatide in postmenopausal women with osteoporosis. J Clin Endocrinol Metab 110(5):e1640\u2013e1652. https:\/\/doi.org\/10.1210\/clinem\/dgae484","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"7999_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/joim.12587","volume":"281","author":"D Sundh","year":"2017","unstructured":"Sundh D, Nilsson AG, Nilsson M, Johansson L, Mellstr\u00f6m D, Lorentzon M (2017) Increased cortical porosity in women with hip fracture. J Intern Med 281(5):496\u2013506. https:\/\/doi.org\/10.1111\/joim.12587","journal-title":"J Intern Med"},{"issue":"11","key":"7999_CR30","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1002\/jbmr.4409","volume":"36","author":"JP Brown","year":"2021","unstructured":"Brown JP, Engelke K, Keaveny TM, Chines A, Chapurlat R, Foldes AJ, Nogues X, Civitelli R, De Villiers T, Massari F, Zerbini CAF, Wang Z, Oates MK, Recknor C, Libanati C (2021) Romosozumab improves lumbar spine bone mass and bone strength parameters relative to alendronate in postmenopausal women: results from the Active-Controlled Fracture Study in Postmenopausal Women With Osteoporosis at High Risk (ARCH) trial. J Bone Miner Res 36(11):2139\u20132152. https:\/\/doi.org\/10.1002\/jbmr.4409","journal-title":"J Bone Miner Res"},{"issue":"1","key":"7999_CR31","doi-asserted-by":"publisher","DOI":"10.1007\/s11657-025-01598-1","volume":"20","author":"J Everts-Graber","year":"2025","unstructured":"Everts-Graber J, Ferrari S, Popp A, Hars M M, Oser S, Studer U, Steiner C, Ziswiler HR, Schmid G, Reichenbach S, Lehmann T, Lamy O, Gonzalez-Rodriguez E (2025) Early transition from short-term romosozumab to antiresorptive therapies: analysis of 26 cases. Arch Osteoporos 20(1):106. https:\/\/doi.org\/10.1007\/s11657-025-01598-1","journal-title":"Arch Osteoporos"},{"issue":"3","key":"7999_CR32","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1016\/S2213-8587(25)00319-5","volume":"14","author":"BZ Leder","year":"2026","unstructured":"Leder BZ, Ramchand SK, Ryan S, Patnaik A, Lee H, Tsai JN (2026) 3 months vs 12 months of romosozumab for postmenopausal osteoporosis (LIDA): an open-label, non-inferiority, randomised controlled tria. Lancet Diabetes Endocrinol 14(3):216\u2013222. https:\/\/doi.org\/10.1016\/S2213-8587(25)00319-5","journal-title":"Lancet Diabetes Endocrinol"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07999-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07999-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:01:53Z","timestamp":1792270913000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07999-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":32,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7999"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07999-3","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alberto Ghielmetti, Giorgia Grassi, Silvia Carrara, Andrea Palermo, Anda Naciu, Eleonora Sargentini, Antonio Salcuni, Fabio Vescini, Marta Zampogna, Anna Atlasova, Sara Rondinella, Roberta Cosso, Iacopo Chiodini, Vittoria Favero, Massimiliano Mazza, Stefano Frara, Giovanna Mantovani, Sabrina Corbetta, Cristina Eller-Vainicher declare that they have no conflict of interest.","order":1,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Declarations"}}]}}